CA2933398C - Biomarkers and methods relating to alzheimer's disease - Google Patents
Biomarkers and methods relating to alzheimer's disease Download PDFInfo
- Publication number
- CA2933398C CA2933398C CA2933398A CA2933398A CA2933398C CA 2933398 C CA2933398 C CA 2933398C CA 2933398 A CA2933398 A CA 2933398A CA 2933398 A CA2933398 A CA 2933398A CA 2933398 C CA2933398 C CA 2933398C
- Authority
- CA
- Canada
- Prior art keywords
- markers
- disease
- protein
- subject
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1322094.2 | 2013-12-13 | ||
| GBGB1322094.2A GB201322094D0 (en) | 2013-12-13 | 2013-12-13 | Methods and compositions relating to alzheimers disease |
| PCT/GB2014/053692 WO2015087087A1 (en) | 2013-12-13 | 2014-12-12 | Biomarkers and methods relating to alzheimer's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2933398A1 CA2933398A1 (en) | 2015-06-18 |
| CA2933398C true CA2933398C (en) | 2023-02-14 |
Family
ID=50030903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2933398A Active CA2933398C (en) | 2013-12-13 | 2014-12-12 | Biomarkers and methods relating to alzheimer's disease |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12345717B2 (enExample) |
| EP (1) | EP3080609B1 (enExample) |
| JP (1) | JP6803230B2 (enExample) |
| CA (1) | CA2933398C (enExample) |
| GB (1) | GB201322094D0 (enExample) |
| WO (1) | WO2015087087A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201504432D0 (en) * | 2015-03-17 | 2015-04-29 | Electrophoretics Ltd | Materials and methods for diagnosis and treatment of alzheimers disease |
| EP3242134A1 (en) * | 2016-05-04 | 2017-11-08 | Euroimmun Medizinische Labordiagnostika AG | Assay for the diagnosis of a neurological disease |
| JPWO2018030252A1 (ja) * | 2016-08-09 | 2019-06-20 | 大塚製薬株式会社 | 尿バイオマーカーを用いたアルツハイマー病の診断補助方法 |
| EP3555841A4 (en) * | 2016-12-13 | 2020-05-20 | Akili Interactive Labs, Inc. | BIOMARKER IDENTIFICATION PLATFORM USING NAVIGATION TASKS AND TREATMENTS USING NAVIGATION TASKS |
| WO2019012671A1 (ja) * | 2017-07-13 | 2019-01-17 | 株式会社Ｍｃｂｉ | 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法 |
| JP7696721B2 (ja) * | 2017-10-31 | 2025-06-23 | ジーイー・ヘルスケア・リミテッド | 認知症の病理学および／または転帰を診断するための医療システム |
| GB201814807D0 (en) * | 2018-09-12 | 2018-10-24 | Univ Newcastle | Dementia Biomarkers |
| KR20210127145A (ko) * | 2019-01-09 | 2021-10-21 | 워싱턴 유니버시티 | 다중 분석 및 이의 사용 방법 |
| US11860170B2 (en) * | 2019-05-16 | 2024-01-02 | Procisedx Inc. | Assay method for the detection of VCAM-1 and alpha-2-macroglobulin in blood |
| US11621087B2 (en) * | 2019-09-24 | 2023-04-04 | International Business Machines Corporation | Machine learning for amyloid and tau pathology prediction |
| JP2023505008A (ja) * | 2019-10-28 | 2023-02-08 | エージェント | アルツハイマー病の無症状期を診断するためのバイオマーカーおよびその使用 |
| KR20230004597A (ko) * | 2020-04-14 | 2023-01-06 | 주식회사 지뉴브 | 신경퇴행성질환 치료제에 대한 반응을 평가하기 위한 방법 및 조성물 |
| WO2022145074A1 (ja) * | 2020-12-28 | 2022-07-07 | 株式会社Mcbi | 判定支援情報生成方法、判定支援情報生成システム、及び情報処理装置 |
| US20250270618A1 (en) * | 2021-03-08 | 2025-08-28 | The Children's Medical Center Corporation | Methods for diagnosis and treatment of alzheimer's disease |
| CN115612728A (zh) * | 2021-07-16 | 2023-01-17 | 深圳先进技术研究院 | 一种神经退行性疾病标志物及其应用 |
| CN114705866A (zh) * | 2022-03-14 | 2022-07-05 | 上海市精神卫生中心（上海市心理咨询培训中心） | 基于血液的遗忘型轻度认知损害早期诊断外周血蛋白标志物、应用及其医疗辅助诊断系统 |
| EP4549945A1 (en) * | 2022-06-28 | 2025-05-07 | Mcbi Inc. | Assessment-supporting information generating method, assessment-supporting information generating system, and information processing device |
| JPWO2024195825A1 (enExample) * | 2023-03-22 | 2024-09-26 | ||
| CN116790745A (zh) * | 2023-07-03 | 2023-09-22 | 复旦大学 | 阿尔茨海默病临床前期疾病转化的标志物及其筛选方法 |
| WO2025057945A1 (ja) * | 2023-09-11 | 2025-03-20 | 国立大学法人三重大学 | 対象が脳アミロイド血管症を有するかを判定するための方法、アルツハイマー病に対する抗アミロイドβ抗体による治療の副作用のリスクまたは存在を判定するための方法、およびアルツハイマー病に対する抗アミロイドβ抗体による治療の対象を選択するための方法、ならびにそのための組成物およびキット |
| CN117538545B (zh) * | 2024-01-09 | 2024-07-05 | 上海众启生物科技有限公司 | 一种用于阿尔茨海默症检测的蛋白抗原组合及应用 |
| WO2025168038A1 (en) * | 2024-02-07 | 2025-08-14 | Kunming Institute Of Zoology, Chinese Academy Of Sciences | Methods and compositions for ameliorating impairment of regenerative and cognitive function |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| AU2002335965A1 (en) * | 2001-11-23 | 2003-06-10 | Syn.X Pharma, Inc. | Pedf biopolymer markers predictive of alzheimers disease |
| CA2745731C (en) | 2002-08-23 | 2015-05-12 | Bayer Schering Pharma Aktiengesellschaft | Biomarkers for diagnosing alzheimer's disease |
| PT2211183E (pt) * | 2003-11-19 | 2013-05-31 | Satoris Inc | Método para diagnosticar e monitorizar a doença de alzheimer |
| GB0421639D0 (en) | 2004-09-29 | 2004-10-27 | Proteome Sciences Plc | Methods and compositions relating to alzheimer's disease |
| DE102010026238B4 (de) * | 2010-06-29 | 2012-08-16 | Schuberth Gmbh | Schutzhelm und Tragkorb für einen Schutzhelm |
-
2013
- 2013-12-13 GB GBGB1322094.2A patent/GB201322094D0/en not_active Ceased
-
2014
- 2014-12-12 JP JP2016538603A patent/JP6803230B2/ja active Active
- 2014-12-12 EP EP14830849.7A patent/EP3080609B1/en active Active
- 2014-12-12 CA CA2933398A patent/CA2933398C/en active Active
- 2014-12-12 WO PCT/GB2014/053692 patent/WO2015087087A1/en not_active Ceased
- 2014-12-12 US US15/104,149 patent/US12345717B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017500562A (ja) | 2017-01-05 |
| JP6803230B2 (ja) | 2020-12-23 |
| US20170219611A1 (en) | 2017-08-03 |
| GB201322094D0 (en) | 2014-01-29 |
| WO2015087087A1 (en) | 2015-06-18 |
| EP3080609A1 (en) | 2016-10-19 |
| US12345717B2 (en) | 2025-07-01 |
| EP3080609B1 (en) | 2021-05-05 |
| CA2933398A1 (en) | 2015-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2933398C (en) | Biomarkers and methods relating to alzheimer's disease | |
| US7897361B2 (en) | Methods of diagnosing Alzheimer's disease | |
| Spellman et al. | Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF | |
| KR20170132318A (ko) | 인지 저하의 위험을 예측하는 방법 | |
| Magliozzi et al. | CSF parvalbumin levels reflect interneuron loss linked with cortical pathology in multiple sclerosis | |
| JP2023525859A (ja) | アルツハイマー病を判定するためのタンパク質マーカー | |
| Wesenhagen et al. | P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles | |
| US20230333121A1 (en) | Methods and compositions relating to biomarkers for neurodegenerative diseases | |
| WO2011092504A2 (en) | Biomarkers | |
| US20250329454A1 (en) | Diagnostic indices for neurodegenerative conditions | |
| AU2011253636B2 (en) | Methods and compositions relating to alzheimer's disease | |
| Santamarina et al. | Extracellular vesicle proteomics identifies novel blood biomarkers for the early diagnosis of status epilepticus | |
| US10502749B1 (en) | Method for patient stratification and drug efficacy monitoring |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20191212 |
|
| EEER | Examination request |
Effective date: 20191212 |
|
| EEER | Examination request |
Effective date: 20191212 |
|
| EEER | Examination request |
Effective date: 20191212 |
|
| EEER | Examination request |
Effective date: 20191212 |